15 Years of Progress for Every Patient Journey 

It started with a napkin sketch on a bar stool on Valencia Street. CEO Mike Fitzgibbons and Stuart Kamin, SVP of Analytics and Innovation, look back at the conversation that sparked Claritas Rx — from their shared roots at Genentech to the early insight that data alone wasn’t enough; patients needed someone connecting it all. They trace the company’s first major inflection point in 2017, when a wave of new customers proved that every manufacturer, not just rare disease innovators, needed a way to understand the patient journey.

What started as needle-in-a-haystack business rules for rare disease patients evolved into AI and machine learning models supporting entire brand portfolios. Mike and Stuart revisit the pivotal 2015 decision to become a full data aggregator rather than outsource it — a harder path that meant building HIPAA-compliant infrastructure and patient-matching capabilities from scratch, but one that gave Claritas Rx a level of confidence in its data, and its conclusions, that no competitor has matched since. They also reflect on a defining 2023 conversation at Asembia, where a major customer realized that white-glove, human-centric patient support doesn’t scale — but technology does.

Fifteen years ago, the napkin captured the mess of data flowing into and out of the biopharma patient services ecosystem. Today’s napkin is bigger: the same problem, drawn for all of healthcare. Mike and Stuart look at what’s next for Claritas Rx — extending care coordination beyond the specialty distribution channel and into the broader provider setting where patients spend the rest of their journey. They also touch on how AI is reshaping their own software development, and why, after 15 years, the need for a Patient Watchtower keeps proving out with manufacturer after manufacturer.

CRO Keith Pensabene and VP of Customer Operations Shelly Howard trace what’s changed — and what hasn’t — over 15 years of Claritas Rx. Shelly reflects on the shift from fragmented, abstract patient data to the granular, actionable insight that lets care teams intervene before a patient drops off therapy. Keith shares what drew him to the company and why the Ascend platform represents the next step in an evolution that’s always centered on one thing: the patient journey.

What sets Claritas Rx apart isn’t just data — it’s the connective tissue that ties an entire care ecosystem together. Keith and Shelly unpack why deep, focused partnerships across specialty pharmacies, hubs, and patient assistance programs are so hard to replicate, and how layering AI into that ecosystem is changing what’s possible: predicting when a patient may go off therapy in time to actually intervene. It’s the difference, they explain, between fragmented tools operating in silos and one true connected view of the patient journey.

CFO Kevin Donalds and VP of Product Meghna Misra dig into the shift powering Claritas Rx’s next phase of growth: moving beyond explaining what already happened to predicting what’s next. Meghna breaks down how machine learning models built on the company’s data foundation don’t just flag which patients are at risk of dropping off therapy. They help explain why, giving manufacturers the ability to act before it’s too late. Kevin connects the dots between that innovation and the business case for investing in it, making the argument that in the AI era, the companies willing to build are the ones that stay relevant.

CFO Kevin Donalds shares what drew him to Claritas Rx: a growth-stage company with a mission he believed in and a product trajectory he could see paying off. Meghna picks up the thread on what that trajectory has actually meant in practice, rebuilding the Ascend platform from the ground up to be multi-tenant, real-time, and API-first, so clients get insight the moment data arrives instead of waiting on scheduled processing. Together, they make the case that AI’s real value isn’t replacing people, it’s amplifying them: giving teams the tools and speed to act faster on what matters.

Kevin and Meghna connect the dots between real time technology and real human stakes: when the Ascend platform delivers insight the moment data arrives, it’s not just a business metric, it’s a difference in someone’s healthcare journey. From there, Kevin makes the financial case for scale, framing Ascend’s ability to handle millions of patients as a shift in total addressable market that could turn Claritas Rx from a fast-growing tech company into a major one. It’s a conversation grounded in data and metrics, but driven by a shared belief that growth and patient impact aren’t competing priorities, they’re the same goal.

CTO Bhupesh Bajaj joins VP of Marketing Elizabeth Marshall fresh off being named to PM360’s Elite 100, a recognition he credits to the whole team’s work. Bhupesh shares what drew him to Claritas Rx (a mission directly tied to patient impact and a company ready for a technology-driven growth leap) and walks through the transformation of the Ascend platform under his leadership: a new data foundation built for reliability, scalability, and security, designed to keep pace as the business and its customer footprint grow.

CTO Bhupesh Bajaj and VP of Marketing Elizabeth Marshall look at how AI is already reshaping Ascend, from surfacing the insights customers need instead of leaving them to dig through reports, to predicting what’s ahead in a patient’s journey and how confident to be in that prediction. Looking forward, Bhupesh sees the next 15 years bringing that same innovation to more products and more customers, while Liz makes the case for getting the story out: Claritas Rx has been one of the best kept secrets in the industry, and it’s time pharmaceutical manufacturers know what’s possible.

Liz and Bhupesh close out their conversation by looking at what sets Claritas Rx apart beyond the technology itself: 15 years of domain expertise that shows up in thought leadership, white papers, and a genuine commitment to being a partner to the industry, whether or not a company is even a customer. Bhupesh teases what’s ahead (more AI, more scalability and security, more workflow and interoperability improvements), and Liz makes the case for why now is the time to tell that story more widely, so the manufacturers who could benefit finally know Claritas Rx exists.